5/29/2013

The FDA awarded breakthrough therapy designation to Alexion Pharmaceuticals' asfotase alfa as a treatment for perinatal-, infantile- and juvenile-onset forms of hypophosphatasia. Asfotase alfa is an enzyme replacement therapy designed to treat, prevent and reverse the complications of hypophosphatasia.

Full Story:
MedicalDaily.com

Related Summaries